3 Undervalued Small Caps In United Kingdom With Insider Activity

In This Article:

The United Kingdom's stock market has been experiencing turbulence, with the FTSE 100 and FTSE 250 indices closing lower amid weak trade data from China and global economic uncertainties. As major economies grapple with post-pandemic recovery challenges, identifying undervalued small-cap stocks with insider activity can offer promising opportunities for investors seeking to navigate these volatile conditions.

Top 10 Undervalued Small Caps With Insider Buying In The United Kingdom

Name

PE

PS

Discount to Fair Value

Value Rating

Bytes Technology Group

24.5x

5.5x

13.26%

★★★★★☆

GB Group

NA

3.0x

34.96%

★★★★★☆

Norcros

7.4x

0.5x

4.23%

★★★★☆☆

Mercia Asset Management

NA

4.8x

49.46%

★★★★☆☆

Foxtons Group

26.4x

1.2x

45.61%

★★★★☆☆

Harworth Group

14.1x

7.4x

-509.59%

★★★★☆☆

CVS Group

22.0x

1.2x

46.51%

★★★★☆☆

Hochschild Mining

NA

1.6x

46.19%

★★★★☆☆

Diaceutics

NA

4.5x

-2.65%

★★★☆☆☆

Hammerson

NA

5.9x

-56.48%

★★★☆☆☆

Click here to see the full list of 21 stocks from our Undervalued UK Small Caps With Insider Buying screener.

Here's a peek at a few of the choices from the screener.

Assura

Simply Wall St Value Rating: ★★★☆☆☆

Overview: Assura is a UK-based healthcare real estate investment trust specializing in the development and management of primary care properties, with a market cap of approximately £2.22 billion.

Operations: The company generates revenue primarily from its core segment, reaching £157.8 million as of the latest period. Gross profit margin has shown a downward trend from 95.76% in June 2017 to 90.81% in March 2024, while net income has fluctuated significantly, turning negative in recent periods with a net loss of £28.8 million by March 2024 due to high non-operating expenses reaching £158.1 million. Operating expenses have remained relatively stable around £14 million recently.

PE: -43.2x

Assura, a specialist healthcare property investor, reported sales of £157.8 million for the year ending March 31, 2024, up from £150.4 million the previous year. Despite a net loss of £28.8 million, down from £119.2 million last year, insider confidence remains high with recent share purchases by executives in June 2024. The company announced a joint venture with Universities Superannuation Scheme Limited worth £250 million to invest in NHS infrastructure and plans to recycle proceeds into new acquisitions and developments across medical centres and broader healthcare markets.

LSE:AGR Share price vs Value as at Aug 2024
LSE:AGR Share price vs Value as at Aug 2024

Harworth Group

Simply Wall St Value Rating: ★★★★☆☆